Article info

Original research
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study

Authors

  1. Correspondence to Dr Ashley Jaksa; ashley.jaksa{at}aetion.com
View Full Text

Citation

Jaksa A, Gibbs L, Kent S, et al
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study

Publication history

  • Received May 12, 2022
  • Accepted October 5, 2022
  • First published October 17, 2022.
Online issue publication 
October 17, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.